Evidence map›Paper›PMID 31671278›Full record

ArticlemAbs

NHDL, a recombinant V

Corinna Lau, Martin Berner McAdam, Grethe Bergseth, Algirdas Grevys, Jack Ansgar Bruun, Judith Krey Ludviksen, Hilde Fure, Terje Espevik, Anders Moen, Jan Terje Andersen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Complement C3b contributes toFrontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Corinna LauResearch Laboratory, Nordland Hospital Trust, Bodø, Norway.ORCID 0000-0003-1750-8065
Martin Berner McAdamDepartment of Immunology, Oslo University Hospital-Rikshospitalet, and Centre for Immune Regulation, Oslo, Norway.ORCID 0000-0001-9385-6964
Grethe BergsethResearch Laboratory, Nordland Hospital Trust, Bodø, Norway.
Algirdas GrevysDepartment of Immunology, Oslo University Hospital-Rikshospitalet, and Centre for Immune Regulation, Oslo, Norway.ORCID 0000-0003-0559-2394
Jack Ansgar BruunDepartment of Medical Biology, Proteomics Platform, University of Tromsø, Tromsø, Norway.ORCID 0000-0003-0614-2790
Judith Krey LudviksenResearch Laboratory, Nordland Hospital Trust, Bodø, Norway.
Hilde FureResearch Laboratory, Nordland Hospital Trust, Bodø, Norway.ORCID 0000-0002-3634-0969
Terje EspevikCentre of Molecular Inflammation Research, and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.ORCID 0000-0003-0354-5068
Anders MoenDepartment of Biosciences, Proteomics core facility, University of Oslo, Oslo, Norway.ORCID 0000-0002-6936-0747
Jan Terje AndersenDepartment of Immunology, Oslo University Hospital-Rikshospitalet, and Centre for Immune Regulation, Oslo, Norway.ORCID 0000-0003-1710-1628
Tom Eirik MollnesResearch Laboratory, Nordland Hospital Trust, Bodø, Norway.ORCID 0000-0002-5785-802X
Nordland Hospital Trust · NOOslo University Hospital · NONorwegian University of Science and Technology · NOUiT The Arctic University of Norway · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produced in our laboratory. So far, no proper IgG2/4 control antibody has been available for controlled validation of IgG2/4 antibody functions. Here, we describe the design of a recombinant control antibody (NHDL), which was generated by combining the variable light (V

Indexed as

AnimalsAntibodies, MonoclonalBiological TherapyBlood ProteinsEpitopesHumansImmunoglobulin GImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsLipopolysaccharide ReceptorsMicePlacebosProtein EngineeringRecombinant Fusion ProteinsSwineAntibodies, MonoclonalBlood ProteinsEpitopesImmunoglobulin GImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsLipopolysaccharide ReceptorsPlacebosRecombinant Fusion Proteinscontrol antibodyhybridIgG2/4Recombinant antibodytherapeutic antibody

Identifiers

PMID31671278
PMCPMC6927768
OpenAlexW2982531139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.